Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Eli Lilly Is Overvalued, Pfizer More Attractive
Eli Lilly Is Overvalued, Pfizer More Attractive
Eli Lilly Is Overvalued, Pfizer More Attractive
Submitted by
admin
on October 27, 2011 - 11:07am
Source:
Seeking Alpha
News Tags:
Eli Lilly
Pfizer
Sanofi
GSK
Headline:
Eli Lilly Is Overvalued, Pfizer More Attractive
Do Not Allow Advertisers to Use My Personal information
